Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,405 across all filing types
Latest filing 2018-06-01 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is explicitly identified by the header 'RNS Number : 0463Q' and contains information related to the 'Transparency Directive' concerning 'Voting Rights and Capital'. It states the total number of voting rights as of a specific date (31 May 2018) and mentions that this figure should be used by shareholders for notification calculations under the UK Financial Conduct Authority's Disclosure and Transparency Rules. This type of mandatory, periodic disclosure regarding the total share capital and voting rights, often disseminated via the Regulatory News Service (RNS), fits best under the general 'Regulatory Filings' category, as there is no specific code for 'Voting Rights Notification' other than DVA (Declaration of Voting Results), which is for results of a vote, not the capital base for future votes. Since it is a standard regulatory announcement distributed via RNS, RNS is the most appropriate classification.
2018-06-01 English
Director Declaration
Board/Management Information Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states it is providing information via 'RNS, the news service of the London Stock Exchange'. The content announces a change in a director's appointment to another company (Sheri McCoy appointed to NovoCure Limited). This type of announcement regarding changes in the board of directors or senior management fits the definition of 'Board/Management Information' (MANG). Although it is distributed via RNS, the core subject matter is management change, making MANG the most specific classification. Since the document is short and reports a specific event rather than being a comprehensive report, MANG is preferred over RNS or RPA.
2018-06-01 English
6-K Filing
Regulatory Filings
2018-06-01 English
6-K Filing
Regulatory Filings
2018-06-01 English
6-K Filing
Regulatory Filings
2018-06-01 English
Update on TERRANOVA PIII trial for Fasenra in COPD
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated May 30, 2018, indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content details the top-line results of a Phase III clinical trial (TERRANOVA) for a drug (Fasenra) in COPD, noting that it did not meet its primary endpoint. This is a specific update on clinical trial progress and results, which is typically released via regulatory news services. Since it is a direct announcement of material information rather than a comprehensive annual report (10-K), interim report (IR), or a general management discussion (MDA), and it is clearly distributed through the RNS system, the most appropriate classification is Regulatory Filings (RNS), as it serves as the general regulatory announcement channel for such news when a more specific category like ER or LTR doesn't perfectly fit the primary purpose (which here is a clinical trial update announcement). Given the context of a clinical trial update disseminated via RNS, RNS is the best fit among the provided options.
2018-05-30 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.